US Senator Dorgan commits to medicine buying freedom, veterans' health

7 October 2009

As the US Congress considers ways to improve the overall health care system, Senator Byron Dorgan (Democrat, North Dakota) spoke at the Grand Forks VA Community Based Outreach Clinic last week of his efforts to bring down the costs of medication by giving Americans the freedom to purchase Food and Drug Administration-approved prescription drugs. Sen Dorgan's legislation, called the 'Pharmaceutical Market Access and Drug Safety Act' is estimated to save $50 billion over the next 10 years.

It has 30 co-sponsors from both parties in the Senate, including Senators Olympia Snowe (Republican, Maine) and John McCain (Republican, Arizona). Senator Dorgan intends to offer the legislation as one of the first amendments to the health care reform bill on the Senate floor. This legislation would save money for North Dakotans and the government, by ultimately forcing drug companies to lower their prices in the USA.

'Prescription drug importation is an important piece in the health care reform puzzle because the high costs of drugs is placing a huge burden on families,' said Sen Dorgan. 'I have heard too many stories of North Dakotans forced to drive to Canada to buy their medications. This legislation will reduce costs to individuals as well as the government, and allow North Dakotans to see that cost savings almost immediately,' he noted.
Current US law permits only pharmaceutical companies to import FDA-approved prescription drugs into the USA, and these imports are estimated to total more than $40 billion a year.

Veterans' health also a priority

Sen Dorgan also told the gathering that he considers ways to improve the overall health care system, Veterans health care remains a top priority

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical